Opinions expressed by Digital Journal contributors are their own. Bringing a new biologic drug from concept to clinic is a complex journey fraught with technical and regulatory hurdles. For ...
The weight-loss drug market is surging, with biotech firms racing to win share in a sector dominated by Novo Nordisk and Eli ...
Lindus Health and Quotient Sciences have announced a strategic partnership to enable enhanced patient recruitment and ...
Recursion Pharmaceuticals leverages AI and machine learning to revolutionize drug discovery, reducing costs and accelerating development, positioning itself as a leader in tech-driven biopharma. The ...
Altasciences, a fully integrated drug development solution company, and VoxCell BioInnovation (“VoxCell”), a leader in 3D bioprinting and human-like tissue modeling, are pleased to announce a ...
Insilico Medicine (3696.HK), a clinical-stage drug discovery and development company driven by generative artificial ...
Genmab will stop development of its experimental antibody therapy to treat cancer that was in late-stage trials, the Danish drugmaker said on Monday. The company had assumed sole responsibility for ...
Recursion Pharmaceuticals (NASDAQ:RXRX) has experienced notable share price fluctuations in 2025, falling 27% year-to-date and trading over 55% beneath its 52-week high of $12. In spite of this ...
ScienceAlert on MSN
New drug stalls Alzheimer's development in breakthrough trial
Growing evidence suggests that the key to treating Alzheimer's is catching it in its earliest stages. Now scientists have developed a promising new drug that seems to be effective at stalling the ...
Insmed said on Wednesday it had discontinued the development of its experimental anti-inflammatory drug to treat a chronic sinus condition after it failed to show benefit in a mid-stage study, sending ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback